Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prokidney (PROK) Common Equity (2022 - 2025)

Prokidney (PROK) has disclosed Common Equity for 4 consecutive years, with -$1.0 billion as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 2.89% to -$1.0 billion in Q3 2025 year-over-year; TTM through Sep 2025 was -$1.0 billion, a 2.89% decrease, with the full-year FY2024 number at -$995.0 million, up 9.83% from a year prior.
  • Common Equity was -$1.0 billion for Q3 2025 at Prokidney, down from -$1.0 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $20.2 million in Q1 2022 to a low of -$1.6 billion in Q1 2023.
  • A 4-year average of -$955.9 million and a median of -$1.0 billion in 2025 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: plummeted 20327.23% in 2023, then soared 31.56% in 2024.
  • Prokidney's Common Equity stood at -$1.1 billion in 2022, then fell by 0.62% to -$1.1 billion in 2023, then grew by 9.83% to -$995.0 million in 2024, then fell by 1.31% to -$1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for PROK's Common Equity are -$1.0 billion (Q3 2025), -$1.0 billion (Q2 2025), and -$998.6 million (Q1 2025).